UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab

Gastroenterology (New York, N.Y. 1943), 2020-08, Vol.159 (2), p.784-787

2020

Volltextzugriff (PDF)

SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges

Journal of Crohn's and colitis, 2021-08, Vol.15 (8), p.1376-1386

2021

Volltextzugriff (PDF)

SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy

The lancet. Gastroenterology & hepatology, 2021-12, Vol.6 (12), p.989-989

2021

Volltextzugriff (PDF)

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy

The lancet. Gastroenterology & hepatology, 2022-11, Vol.7 (11), p.984-985

2022

Volltextzugriff (PDF)

Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease

The lancet. Gastroenterology & hepatology, 2022-06, Vol.7 (6), p.507-507

2022

Volltextzugriff (PDF)

Reply

Gastroenterology (New York, N.Y. 1943), 2021-01, Vol.160 (1), p.471-472

2021

Volltextzugriff (PDF)

Tu1757 MUCOSA-ASSOCIATED MICROBIOME SIGNATURE PREDICTS THERAPY RESPONSE TO ANTI-TNFA IN CROHN'S DISEASE

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1409-S-1409

2024

Volltextzugriff (PDF)

Tu1767 HIGHER PREDICTIVE POWER OF EPIGENETIC SIGNATURES FOR RESPONSE TO VEDOLIZUMAB AND USTEKINUMAB IN ANTI-TNF NAÏVE PATIENTS WITH ACTIVE CROHN'S DISEASE

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1413-S-1413

2024

Volltextzugriff (PDF)

Mo1505: PERIPHERAL BLOOD DNA METHYLATION BIOMARKERS ACCURATELY PREDICT CLINICAL- AND ENDOSCOPIC RESPONSE TO VEDOLIZUMAB IN A REAL-LIFE COHORT OF CROHNS DISEASE PATIENTS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-794-S-794

2022

Volltextzugriff (PDF)

568 EPIGENOME-WIDE PERIPHERAL BLOOD DNA METHYLATION PROFILES ACCURATELY PREDICT ENDOSCOPIC- AND CLINICAL RESPONSE AND REMAIN HIGHLY STABLE DURING INDUCTION AND MAINTENANCE TREATMENT WITH ADALIMUMAB, VEDOLIZUMAB AND USTEKINUMAB IN CROHN'S DISEASE PATIENTS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-101-S-101

2023

Volltextzugriff (PDF)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-278-S-278

2022

Volltextzugriff (PDF)

887: WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-216-S-216

2022

Volltextzugriff (PDF)

Tu1545: TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-1004-S-1005

2022

Volltextzugriff (PDF)

Reply

Gastroenterology (New York, N.Y. 1943), 2021-01, Vol.160 (1), p.471

2021

Volltextzugriff (PDF)

Reply

Gastroenterology (New York, N.Y. 1943), 2021-01, Vol.160 (1), p.471-472

2021

Volltextzugriff (PDF)

Chemokine receptor CCR5 polymorpidsms do not affect disease progression in hepatitis C virus infection

Gastroenterology (New York, N.Y. 1943), 2000-04, Vol.118 (4), p.A943-A943

2000

Volltextzugriff (PDF)

Guidelines for the management of inflammatory bowel disease in adults

Gut, 2011-05, Vol.60 (5), p.571-607

2011

Volltextzugriff (PDF)

Review article: impact of cigarette smoking on intestinal inflammation—direct and indirect mechanisms

Alimentary pharmacology & therapeutics, 2020-06, Vol.51 (12), p.1268-1285

2020

Volltextzugriff (PDF)

Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease

Nature genetics, 2017-02, Vol.49 (2), p.262-268

2017

Volltextzugriff (PDF)

Fine-mapping inflammatory bowel disease loci to single-variant resolution

Nature (London), 2017-07, Vol.547 (7662), p.173-178

2017

Volltextzugriff (PDF)

Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers

Gut, 2011-01, Vol.60 (1), p.3-9

2011

Volltextzugriff (PDF)

Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease

Journal of Crohn's and colitis, 2021-05, Vol.15 (5), p.699-708

2021

Volltextzugriff (PDF)

Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study

Alimentary pharmacology & therapeutics, 2023-02, Vol.57 (4), p.399-408

2023

Volltextzugriff (PDF)

1 – 25 von 182

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(149)

Publikationsform

Artikel
(181)
Tagungsberichte
(1)

Sprache

Englisch
(182)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(132)
Humans
(126)
Life Sciences & Biomedicine
(124)
Gastroenterology & Hepatology
(82)
Inflammatory Bowel Disease
(62)
Male
(52)
Crohn Disease - Genetics
(51)
Female
(48)
Adult
(45)
Genetic Predisposition To Disease
(39)
Crohn's Disease
(37)
Colitis, Ulcerative - Genetics
(36)
Biological And Medical Sciences
(33)
Medical Sciences
(32)
Ulcerative Colitis
(32)
Inflammatory Bowel Diseases - Genetics
(31)
Middle Aged
(29)
Gastroenterology. Liver. Pancreas. Abdomen
(28)
Medicin Och Hälsovetenskap
(28)
Other Diseases. Semiology
(28)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab

SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges

SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy

Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease

Reply

Tu1757 MUCOSA-ASSOCIATED MICROBIOME SIGNATURE PREDICTS THERAPY RESPONSE TO ANTI-TNFA IN CROHN'S DISEASE

Tu1767 HIGHER PREDICTIVE POWER OF EPIGENETIC SIGNATURES FOR RESPONSE TO VEDOLIZUMAB AND USTEKINUMAB IN ANTI-TNF NAÏVE PATIENTS WITH ACTIVE CROHN'S DISEASE

Mo1505: PERIPHERAL BLOOD DNA METHYLATION BIOMARKERS ACCURATELY PREDICT CLINICAL- AND ENDOSCOPIC RESPONSE TO VEDOLIZUMAB IN A REAL-LIFE COHORT OF CROHNS DISEASE PATIENTS

568 EPIGENOME-WIDE PERIPHERAL BLOOD DNA METHYLATION PROFILES ACCURATELY PREDICT ENDOSCOPIC- AND CLINICAL RESPONSE AND REMAIN HIGHLY STABLE DURING INDUCTION AND MAINTENANCE TREATMENT WITH ADALIMUMAB, VEDOLIZUMAB AND USTEKINUMAB IN CROHN'S DISEASE PATIENTS

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE

887: WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)

Tu1545: TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE

Reply

Reply

Chemokine receptor CCR5 polymorpidsms do not affect disease progression in hepatitis C virus infection

Guidelines for the management of inflammatory bowel disease in adults

Review article: impact of cigarette smoking on intestinal inflammation—direct and indirect mechanisms

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease

Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease

Fine-mapping inflammatory bowel disease loci to single-variant resolution

Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers

Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease

Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study

Bayesian refinement of association signals for 14 loci in 3 common diseases

Suchergebnisse filtern